China NT Pharma Group Company Limited provides unaudited consolidated earnings guidance for the six months ended June 30, 2017. The Group expects to record an increase in net profit by approximately 50% for the six months ended 30 June 2017 as compared to the corresponding period of 2016. Such increase is primarily attributable to innovative drug Xi Di Ke and brand-name drug Miacalcic which contributed to the profit of the Group.